{"id":87464,"date":"2022-11-28T13:30:00","date_gmt":"2022-11-28T12:30:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=87464"},"modified":"2022-11-28T13:29:42","modified_gmt":"2022-11-28T12:29:42","slug":"catalym-series-c-financing-round","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/","title":{"rendered":"Catalym secures 50 million euros"},"content":{"rendered":"
\n

After a Series B round of 50 million euros two years ago<\/a> Catalym has raised another \u20ac50 million. In addition to Bavaria Capital<\/a> Forbion, Novartis Venture Fund, Vesalius Biocapital III, BioGeneration Ventures, and Coparion are also among the existing investors. Brandon Capital and Jeito Capital are joining as new lead investors.<\/p>\n\n\n\n

With the new financial resources, the IZB<\/a>-Company will initiate the second phase of the development program for its drug candidate Visugromab. Visugromab is designed to neutralize a specific protein that tumors use to protect themselves from the body's immune system. This should make tumors accessible to the immune system again, thus strengthening the immune response.<\/p>\n\n\n\n

Approval-relevant studies<\/h2>\n\n\n\n

Phil L'Huillier<\/strong>, CEO at Catalym, says:<\/p>\n\n\n\n

"The successfully completed Series C financing round is further confirmation that visugromab is emerging as a new immunotherapeutic cancer drug with the potential to transform the immuno-oncology landscape. We greatly appreciate the commitment of our new and existing investors and will work with them to advance further clinical development toward pivotal trials."<\/p><\/blockquote>\n\n\n\n

As part of the successful financing round, Jonathan Tobin, Partner at Brandon Capital, and Andreas Wallnoefer, Partner at Jeito Capital, will also be appointed as new members to Catalym's Advisory Board.<\/p>\n\n\n\n

Jonathan Tobin<\/strong> from Brandon Capital<\/a> says about the current financing round:<\/p>\n\n\n\n

"We are excited by the extremely promising clinical data Catalym has generated in a short period of time. They demonstrate the company's ability to advance a program focused on a novel target molecule and develop a targeted antibody to generate adaptive immune responses in end-stage cancer patients. We look forward to supporting the Catalym team in advancing visugromab into late-stage clinical development and further investigating the role of GDF-15 in immunosuppression."<\/p><\/blockquote>\n\n\n\n

\u201cGreat potential to improve patients\u2019 lives\u201d<\/h2>\n\n\n\n

Andreas Wallnoefer<\/strong> from Jeito Capital<\/a>\u00a0added:<\/p>\n\n\n\n

"Visugromab has shown promising results in initial studies, leading to several impressive responses in patients with advanced tumors. With its significant efficacy profile and good tolerability, the drug has great potential to improve patients' lives and become an important part of cancer immunotherapy regimens."<\/p><\/blockquote>\n\n\n\n

George Ried, <\/strong>Managing Director of Bayern Kapital, says:<\/p>\n\n\n\n

"With the monoclonal antibody visugromab, Catalym is developing a novel cancer immunotherapy for patients with advanced tumors who do not respond or no longer respond to current therapeutic approaches such as checkpoint inhibitors. Since our initial investment in September 2020, the company has taken another major step in clinical development with promising results. We are very pleased to continue this promising path together with the Catalym team."<\/p><\/blockquote>\n\n\n\n

Bayern Kapital invested millions of euros from funds of the Growth Fund Bavaria 2 (WFB 2)<\/a>Initiated by the Bavarian Ministry of Economic Affairs and managed by Bayern Kapital, WFB 2 is open to investments of between 2 and 10 million euros.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Catalym raises \u20ac50 million in a Series C round. The Martinsried-based biotech startup plans to invest the newly raised capital in further clinical testing of its drug candidate Visugromab.<\/p>","protected":false},"author":24,"featured_media":66785,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,1,5635],"tags":[371,4129,52,1499],"acf":[],"yoast_head":"\nCatalym sichert sich 50 Millionen Euro - Munich Startup<\/title>\n<meta name=\"description\" content=\"Catalym, das Biotech-Startup mit Sitz in Martinsried, sammelt in einer Series-C-Runde 50 Millionen Euro ein.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalym sichert sich 50 Millionen Euro - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Catalym, das Biotech-Startup mit Sitz in Martinsried, sammelt in einer Series-C-Runde 50 Millionen Euro ein.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-28T12:30:00+00:00\" \/>\n<meta name=\"author\" content=\"Regina Bruckschl\u00f6gl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Regina Bruckschl\u00f6gl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/\",\"name\":\"Catalym sichert sich 50 Millionen Euro - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\",\"datePublished\":\"2022-11-28T12:30:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f\"},\"description\":\"Catalym, das Biotech-Startup mit Sitz in Martinsried, sammelt in einer Series-C-Runde 50 Millionen Euro ein.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Catalym\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalym sichert sich 50 Millionen Euro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f\",\"name\":\"Regina Bruckschl\u00f6gl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g\",\"caption\":\"Regina Bruckschl\u00f6gl\"},\"description\":\"Nach eigenen Startup-Erfahrungen blickt sie als Redakteurin von Munich Startup nun aus einer anderen Perspektive auf die M\u00fcnchner Startup-Szene \u2013 und entdeckt dabei jeden Tag, wie vielf\u00e4ltig das M\u00fcnchner \u00d6kosystem ist. Startup Stories, die erz\u00e4hlt werden wollen!\",\"sameAs\":[\"https:\/\/cms.munich-startup.net\"],\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/regina\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalym secures 50 million euros - Munich Startup","description":"Catalym, the biotech startup based in Martinsried, raises 50 million euros in a Series C round.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/","og_locale":"en_US","og_type":"article","og_title":"Catalym sichert sich 50 Millionen Euro - Munich Startup","og_description":"Catalym, das Biotech-Startup mit Sitz in Martinsried, sammelt in einer Series-C-Runde 50 Millionen Euro ein.","og_url":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2022-11-28T12:30:00+00:00","author":"Regina Bruckschl\u00f6gl","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Regina Bruckschl\u00f6gl","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/","url":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/","name":"Catalym secures 50 million euros - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","datePublished":"2022-11-28T12:30:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f"},"description":"Catalym, the biotech startup based in Martinsried, raises 50 million euros in a Series C round.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","width":1920,"height":1280,"caption":"Catalym"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/en\/87464\/catalym-series-c-financing-round\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Catalym sichert sich 50 Millionen Euro"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f","name":"Regina Bruckschl\u00f6gl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g","caption":"Regina Bruckschl\u00f6gl"},"description":"After her own startup experiences, she now looks at the Munich startup scene from a different perspective as an editor at Munich Startup \u2013 and discovers every day how diverse the Munich ecosystem is. Startup stories that beg to be told!","sameAs":["https:\/\/cms.munich-startup.net"],"url":"https:\/\/cms.munich-startup.net\/en\/author\/regina\/"}]},"og_image":[{"width":1920,"height":1280,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1669638586:33","_edit_last":"33","_yoast_wpseo_focuskw":"Catalym","_yoast_wpseo_metadesc":"Catalym, das Biotech-Startup mit Sitz in Martinsried, sammelt in einer Series-C-Runde 50 Millionen Euro ein.","_yoast_wpseo_linkdex":"75","_thumbnail_id":"66785","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"30","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"0","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"2","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/87464"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=87464"}],"version-history":[{"count":4,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/87464\/revisions"}],"predecessor-version":[{"id":87473,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/87464\/revisions\/87473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/66785"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=87464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=87464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=87464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}